OptMed, which is commercializing topical tissue adhesives used in surgery, withdrew its plans for an initial public offering on Monday. It originally filed in June 2022 with a proposed deal size of $23 million.
The New York, NY-based company was founded in 2007 and had planned to list on the Nasdaq under the symbol OMED. EF Hutton was set to be the sole bookrunner on the deal.
